2-Year Long-Term Study | Safety | PNH | FABHALTA® (iptacopan)

Safety and side effects. Theresa, a person living with PNH and taking FABHALTA, compensated for her time

A long-term study of adults with PNH and Hb <10 g/dL who completed the APPLY or APPOINT studies and continued taking FABHALTA.

The long-term safety of FABHALTA was studied through 2 years

Adverse reactions reported in ≥10% of people

Chart analyzing the adverse reaction rate for FABHALTA during the 2-year follow-up study.

Four people discontinued FABHALTA during the follow-up study: 2 due to death, 1 due to an adverse reaction, and 1 due to physician decision.

Data on clinical breakthrough hemolysis

Data on major adverse vascular events

ULTOMIRIS (ravulizumab-cwvz) and SOLIRIS (eculizumab) are registered trademarks of Alexion Pharmaceuticals, Inc.

Want to see the impact of FABHALTA on PNH?

See the Results

Ready to go from “fine” to FABHALTA?